Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1093/GERONI/IGAF021 | ||||
| Año | 2025 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Background and objective: Sarcopenic obesity (SO), obesity, and sarcopenia have been related to adverse events in older adults, raising the question about the role of each component in the risk associated with SO. The objective of this manuscript is to evaluate the role of sarcopenia, obesity, and its interaction in the risks (frailty, disability, mortality) associated with sarcopenic obesity. Research Design and Methods: Data from the Toledo Study of Healthy Aging (TSHA) were used. This is a cohort-based study composed of community-dwelling adults >= 65 years. Obesity (Body Mass Index-BMI >= 30) and sarcopenia (the Foundation for the National Institutes of Health-FNIH criteria, standardized to our population) were assessed at baseline. Frailty, through the Frailty Phenotype (FP) and the Frailty Trait scale-5 (FTS5), and disability (Katz Index) were evaluated at baseline. Mortality, frailty, and disability were assessed at follow-up. Logistic (odds ratio, OR) and Cox (hazard ratio, HR) regression models were computed to assess the associations. Results: A total of 1 538 (74.73 years, 45.51% men) individuals were included. Cross-sectionally, SO, sarcopenia, and obesity were significantly associated with the risk of frailty and disability. Longitudinally, Sarcopenia was associated with all the adverse events (ORs/HRs ranged from 1.41 to 4.14, p-value < .05); whereas SO [FP, OR (95% confidence interval-CI): 4.27 (2.05, 8.93); FTS5, OR (95% CI): 6.14 (3.58, 10.51), p-value < .001] and obesity [FP, OR (95% CI): 3.10 (1.95, 4.94), p-value < 0.001; FTS5, OR (95% CI): 2.26 (1.17, 4.35), p-value 0.015] was only associated with incident frailty. Sarcopenia added risk to obesity for frailty (FP and FTS5) whereas obesity only did for frailty (FTS5) in sarcopenic individuals. The interaction between sarcopenia and obesity was not associated with any outcome. Discussion and Implications: Sarcopenia and obesity provide each other an additive risk for frailty, but not a multiplicative (ie, interaction) one, in sarcopenic obesity. Sarcopenia is the mean factor accounting for the associated risk.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Alvarez-Bustos, Alejandro | - |
Inst Salud Carlos III - España
Inst Invest IdiPaz - España Centro de Investigación Biomédica en Red Sobre Fragilidad y Envejecimiento Saludable - España Instituto de Investigación Sanitaria del Hospital Universitario La Paz - España |
| 2 | Carnicero, Jose A. | - |
Inst Salud Carlos III - España
Hosp Univ Getafe - España Centro de Investigación Biomédica en Red Sobre Fragilidad y Envejecimiento Saludable - España Hospital Universitario de Getafe - España |
| 3 | Sepulveda-Loyola, Walter | - |
Univ Las Amer - Chile
Universidad de Las Américas Chile - Chile |
| 4 | Molina-Baena, Begona | - |
Hosp Univ La Princesa - España
Hospital Universitario de la Princesa - España |
| 5 | Garcia-Garcia, Francisco J. | - |
Inst Salud Carlos III - España
Hosp Virgen Valle - España Centro de Investigación Biomédica en Red Sobre Fragilidad y Envejecimiento Saludable - España Complejo Hospitalario de Toledo - España |
| 6 | Rodriguez-Manas, Leocadio | - |
Inst Salud Carlos III - España
Hosp Univ Getafe - España Centro de Investigación Biomédica en Red Sobre Fragilidad y Envejecimiento Saludable - España Hospital Universitario de Getafe - España |
| Fuente |
|---|
| European Regional Development Fund |
| Instituto de Salud Carlos III |
| Seventh Framework Programme |
| Spanish Ministry of Economy, Industry and Competitiveness |
| Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable |
| Innovative Medicines Initiative |
| Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España |
| Fundación Francisco Soria Melguizo |
| Centro de Investigacion Biomedica en Red en Fragilidad y Envejecimiento Saludable |
| European Regional Development Funds (Instituto de Salud Carlos III) |
| Papel de la disfuncion MITOcondrial en la relacion entre multimorbilidad cronica y deterioro FUNcional en ancianos. El Proyecto MITOFUN, Fundacion Francisco Soria Melguizo |
| Innovative Medicines Initiative Joint Undertaking from the European Union' Seventh Framework Programme (FP7/2007-2013) |
| Agradecimiento |
|---|
| TSHA research was funded by grants from the Spanish Ministry of Economy, Industry and Competitiveness, cofinanced by the European Regional Development Funds (Instituto de Salud Carlos III, PI20/00977) and the Centro de Investigacion Biomedica en Red en Fragilidad y Envejecimiento Saludable (CB16/10/00464), the Papel de la disfuncion MITOcondrial en la relacion entre multimorbilidad cronica y deterioro FUNcional en ancianos. El Proyecto MITOFUN, Fundacion Francisco Soria Melguizo (Section 2/2020), Innovative Medicines Initiative Joint Undertaking under grant agreement no115621, resources of which are composed of financial contribution from the European Union' Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. |
| TSHA research was funded by grants from the Spanish Ministry of Economy, Industry and Competitiveness, cofinanced by the European Regional Development Funds (Instituto de Salud Carlos III, PI20/00977) and the Centro de Investigaci\u00F3n Biom\u00E9dica en Red en Fragilidad y Envejecimiento Saludable (CB16/10/00464), the Papel de la disfunci\u00F3n MITOcondrial en la relaci\u00F3n entre multimorbilidad cr\u00F3nica y deterioro FUNcional en ancianos. El Proyecto MITOFUN, Fundaci\u00F3n Francisco Soria Melguizo (Section 2/2020), Innovative Medicines Initiative Joint Undertaking under grant agreement n\u25E6115621, resources of which are composed of financial contribution from the European Union\u2019 Seventh Framework Programme (FP7/2007-2013) and EFPIA companies\u2019 in kind contribution. We would like to thank the participants, cohort members, and team researcher members. |